In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Crude awakening: Kapoor’s renewable-material protest art installed on Shell gas platform
In the North Sea, protest art made by Anish Kapoor, using renewable materials such as used coffee grounds and beetroot powder, has been installed...
Tiny Vinyl to release tiny, biobased PVC records
In the US, a startup called Tiny Vinyl has created cute, mini, vinyl records out of bio-attributed polyvinyl chloride. The 4-inch mini singles play...
Fun with Fungi: Japanese designers create mycelium block-growing kit
In Japan, designers have created a biomaterial kit for growing toy blocks out mycelium. Dubbed MYMORI, the kit includes block molds and a mycelium...